A Study Comparing Two Ways of Taking Olomorasib (LY3537982) in Healthy Participants
← catalyst calendarNCT07794592 · readout ≤ 60 d
Sponsored by Eli Lilly and Company (industry) · LLY — their whole pipeline →.
Phase
Phase 1
Status
Not yet recruiting
Study type
Interventional
Design
Randomized · None · Basic science
Enrollment
24estimated
Sites
1
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-31
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | Aug 2026 | estimated | When the study began enrolling |
| Primary completion | Oct 2026 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Oct 2026 | estimated | The whole study's end, after follow-up |
| First posted | 2026-08-31 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-31 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Healthy Volunteers
Interventions
- Drug: Olomorasib test — also filed as LY3537982
- Drug: Olomorasib reference — also filed as LY3537982
Primary outcome
what the primary-completion date above is the date OFPharmacokinetics: Maximum Concentration (Cmax) of olomorasib
measured Day 1 to Day 7
Related
LLY · their whole pipeline · Who in Congress owns LLY? · Executive-branch trades in LLY
LLY's other studiesmost recently updated first
- A Study of LY3549492 in Adults With Obesity or Overweight With Type 2 Diabetes Phase 2 · Terminated
- A Study of Orforglipron in Participants With Overweight at Risk of Development of Obesity-Related Complications or Progression to Class 1 Obesity Phase 3 · Not yet recruiting
- A Study of Brenipatide (LY3537031) in Adult Participants With Major Depressive Disorder Phase 3 · Not yet recruiting
- A Master Protocol Studying Multiple Amyloid-Targeting Therapies in Healthy Participants and Participants With Alzheimer's Disease Phase 1 · Not yet recruiting
- A Study of Orforglipron (LY3502970) in Chinese Participants With Obesity or Overweight and Weight-Related Health Problems Phase 3 · Not yet recruiting
Permalink · LLY's whole pipeline · Catalyst calendar · Every registered study · What changed